Abstract
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in the treatment of heart failure with reduced ejection fraction (HFrEF). Here, we analyzed the inotropic effects of danicamtiv in detail. To this end, changes in sarcomere length and intracellular Ca2+ levels were monitored in parallel, in enzymatically isolated canine cardiomyocytes, and detailed echocardiographic examinations were performed in anesthetized rats in the absence or presence of danicamtiv. The systolic and diastolic sarcomere lengths decreased; contraction and relaxation kinetics slowed down with increasing danicamtiv concentrations without changes in intracellular Ca2+ transients in vitro. Danicamtiv evoked remarkable increases in left ventricular ejection fraction and fractional shortening, also reflected by changes in systolic strain. Nevertheless, the systolic ejection time was significantly prolonged, the ratio of diastolic to systolic duration was reduced, and signs of diastolic dysfunction were also observed upon danicamtiv treatment in vivo. Taken together, danicamtiv improves cardiac systolic function, but it can also limit diastolic performance, especially at high drug concentrations.
Funder
National Research, Development, and Innovation Fund
European Union and the European Regional Development Fund
National Research, Development, and Innovation Fund of Hungary
Hungarian Academy of Sciences
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference41 articles.
1. Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes;Shah;J. Am. Coll. Cardiol.,2017
2. Heart Failure: A Class Review of Pharmacotherapy;Shah;P T A Peer-Rev. J. Formul. Manag.,2017
3. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure;McDonagh;Eur. Heart J.,2021
4. Cardiac Myosin Activation for the Treatment of Systolic Heart Failure;Bernier;J. Cardiovasc. Pharmacol.,2021
5. Alsulami, K., and Marston, S. (2020). Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. Int. J. Mol. Sci., 21.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献